The management of Israeli pharma group Teva has laid out its strategy for a return to growth after a challenging few years, with a greater emphasis on innovative medicines and a focus on complex, higher value products in its generics business.

Attuned to the burdens of people living with Huntington’s disease (HD) chorea and tardive dyskinesia (TD), Teva has been eager to cut the amount of pills patients need to take in half. Now, it's scored an FDA approval to do just that.

Teva Pharmaceutical Industries’ US affiliate Teva Pharmaceuticals has reported findings from the ARC-HD clinical trial of Austedo (deutetrabenazine) tablets to treat patients with chorea linked to Huntington’s disease (HD).

The multicentre, three-year, single-arm, open-label, two-cohort, extension trial assessed the safety and tolerability of long-term use of Austedo in these patients.

As Teva leans on tardive dyskinesia med Austedo for growth, the company can feel comfortable that it has a long runway clear from generics⁠—at least from two prominent challengers.

Teva has closed the books on its patent infringement lawsuit against Aurobindo over the Indian company's application to market a generic of Austedo.

Teva has high hopes for its tardive dyskinesia (TD) treatment Austedo. Now, the company has one less generic drugmaker to worry about as a threat to its core growth driver.

On Monday, Teva revealed that it has agreed to a settlement with Lupin that will allow the Mumbai-based generics manufacturer to sell its version of Austedo in the U.S. beginning in April 2033.

Fresh off a global cost-cutting spree and with Teva's branded medicines lagging against their rivals, CEO Kåre Schultz is again changing his executive ranks.

Brendan O’Grady, who Schultz previously tapped to lead Teva’s North American commercial business, is leaving the company to pursue other opportunities, the company said. Teva’s executive vice president of marketing and portfolio in international markets, Sven Dethlefs, is taking the post.

Teva's first DTC campaign for tardive dyskinesia (TD) drug Austedo launches into a suddenly competitive TV ad space for the rare condition. It joins Neurocrine Biosciences' Ingrezza campaign that began in April.

Teva is joining the marketing push in tardive dyskinesia with its first consumer campaign for Austedo, executives said Wednesday..

Teva’s campaign will be the second tardive dyskinesia effort in market. Rival Neurocrine Biosciences' unbranded awareness effort “Talk About TD” has been running on TV and digital since 2019.

Riding high on the launch of Huntington's disease and tardive dyskinesia (TD) med Austedo, Teva figures the med can top $2 billion, CEO Kare Schultz said, highlighting a bright spot in a decidedly gray picture at the drugmaker. But analysts aren't so sure Austedo can pull it off.